Prices are updated after-hours
Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : BLUE    crawled date : 2020 - 12 - 04    save search
Magenta Therapeutics and bluebird bio Announce a Phase 2 Clinical Trial Collaboration to Evaluate Magenta’s MGTA-145 for Mobilizing and Collecting Stem Cells in Adults and Adolescents with Sickle Cell Disease
Published: 2020-12-04 (Crawled : 16:00) - biospace.com/
BLUE | $0.9668 -2.37% -2.43% 8.7M twitter stocktwits trandingview |
Health Technology
 | | O: -0.28% H: 2.43% C: 0.15%
collaboration disease stem cell trial phase 2
Gainers vs Losers
56% 44%

Top 10 Gainers
INVO | $1.76 131.58% 56.82% 230M twitter stocktwits trandingview |
Health Technology
SINT | $0.0365 59.39% 37.26% 470M twitter stocktwits trandingview |
Health Technology
WISA 4 | $9.19 50.66% 33.7% 65M twitter stocktwits trandingview |
Electronic Technology
EDBL | News | $6.73 47.91% 32.39% 13M twitter stocktwits trandingview |

GCTK | $0.715 36.27% 26.62% 640K twitter stocktwits trandingview |
Manufacturing
TCON | $2.33 36.26% 26.61% 2M twitter stocktwits trandingview |
Health Technology
TIRX | $0.48 6.43% 24.58% 4.8M twitter stocktwits trandingview |

KZIA | $0.38 30.58% 23.42% 300K twitter stocktwits trandingview |
Health Technology
VNDA | News | $5.23 29.14% 22.56% 24M twitter stocktwits trandingview |
Health Technology
ATNF | $1.91 29.05% 22.51% 310K twitter stocktwits trandingview |

Your saved searches
Save your searches and get alerts when important news are released.